A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapy
Latest Information Update: 15 Sep 2013
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Large cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 15 Sep 2013 New trial record